Renaissance Technologies
PVLA

Renaissance Technologies’s Palvella Therapeutics PVLA Stock Holding History

Renaissance Technologies’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.24M Sell
17,970
-4,560
-20% -$476K ﹤0.01% 1838
2025
Q4 		$2.36M Sell
22,530
-67,167
-75% -$5.73M ﹤0.01% 1760
2025
Q3 		$5.62M Buy
89,697
+22,839
+34% +$1.02M 0.01% 1417
2025
Q2 		$1.51M Buy
66,858
+51,600
+338% +$1.21M ﹤0.01% 2286
2025
Q1 		$427K Sell
15,258
-6,113
-29% -$118K ﹤0.01% 2804
2024
Q4 		$256K Sell
21,371
-10,800
-34% -$170K ﹤0.01% 3087
2024
Q3 		$533K Buy
32,171
+20,700
+180% +$302K ﹤0.01% 2765
2024
Q2 		$113K Sell
11,471
-6,399
-36% -$72.2K ﹤0.01% 3165
2024
Q1 		$262K Buy
17,870
+4,557
+34% +$63.5K ﹤0.01% 3135
2023
Q4 		$194K Buy
13,313
+8,547
+179% +$157K ﹤0.01% 3142
2023
Q3 		$114K Buy
4,766
+147
+3% +$3.16K ﹤0.01% 3220
2023
Q2 		$61K Sell
4,619
-198
-4% -$12K ﹤0.01% 3579
2023
Q1 		$376K Sell
4,817
-3,770
-44% -$437K ﹤0.01% 3014
2022
Q4 		$714K Sell
8,587
-552
-6% -$44.4K ﹤0.01% 2729
2022
Q3 		$841K Buy
9,139
+1,888
+26% +$243K ﹤0.01% 2603
2022
Q2 		$1.08M Buy
7,251
+2,569
+55% +$469K ﹤0.01% 2658
2022
Q1 		$1.14M Buy
4,682
+338
+8% +$88.8K ﹤0.01% 2656
2021
Q4 		$1.31M Buy
4,344
+583
+16% +$187K ﹤0.01% 2458
2021
Q3 		$1.55M Sell
3,761
-6,379
-63% -$2.22M ﹤0.01% 2283
2021
Q2 		$3.11M Sell
10,140
-6,474
-39% -$1.42M ﹤0.01% 1938
2021
Q1 		$3.42M Sell
16,614
-1,192
-7% -$261K ﹤0.01% 1886
2020
Q4 		$3.56M Sell
17,806
-1,496
-8% -$311K ﹤0.01% 1804
2020
Q3 		$3.2M Sell
19,302
-2,734
-12% -$622K ﹤0.01% 1845
2020
Q2 		$5.46M Sell
22,036
-1,015
-4% -$237K ﹤0.01% 1589
2020
Q1 		$4.21M Sell
23,051
-1,738
-7% -$438K ﹤0.01% 1671
2019
Q4 		$7.18M Sell
24,789
-2,564
-9% -$711K 0.01% 1651
2019
Q3 		$7.46M Buy
27,353
+244
+0.9% +$94.5K 0.01% 1581
2019
Q2 		$10.2M Buy
27,109
+1,011
+4% +$302K 0.01% 1395
2019
Q1 		$6.99M Buy
26,098
+1,289
+5% +$306K 0.01% 1592
2018
Q4 		$5.28M Buy
24,809
+7,504
+43% +$2.33M 0.01% 1696
2018
Q3 		$7.75M Sell
17,305
-1,728
-9% -$751K 0.01% 1517
2018
Q2 		$7.72M Sell
19,033
-90
-0.5% -$42.8K 0.01% 1507
2018
Q1 		$10.4M Buy
19,123
+10,997
+135% +$6.81M 0.01% 1338
2017
Q4 		$4.91M Buy
8,126
+3,162
+64% +$1.47M 0.01% 1819
2017
Q3 		$2.29M Buy
4,964
+3,515
+243% +$1.5M ﹤0.01% 2230
2017
Q2 		$586K Sell
1,449
-1,731
-54% -$506K ﹤0.01% 2723
2017
Q1 		$661K Buy
+3,180
New +$563K ﹤0.01% 2681
2016
Q4 		– Sell
-539
Closed -$79K – 3496
2016
Q3 		$79K Buy
+539
New +$71.6K ﹤0.01% 3211

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies's PVLA Position: Q1 2026 in Review

Renaissance Technologies reduced its Palvella Therapeutics (PVLA) stake by 20% in Q1 2026, selling an estimated $476K and leaving 17,970 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1838.

Renaissance Technologies first reported a position in PVLA in Q3 2016 and has held it in 38 quarters since. The position peaked at $10.4M in Q1 2018. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Renaissance Technologies held 17,970 shares of Palvella Therapeutics worth $2.24M as of Q1 2026.
  • Renaissance Technologies sold 4,560 Palvella Therapeutics shares in Q1 2026, an estimated $476K.
  • Palvella Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1838 holding.
  • Renaissance Technologies first reported a position in Palvella Therapeutics in Q3 2016 and has held it in 38 quarters since.
  • Renaissance Technologies's Palvella Therapeutics position peaked at $10.4M in Q1 2018.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.